The Utility of Regional Bioimpedance in Chronically Ventilated Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronically ventilated patients will be hemodynamically measured by bioimpedance (NiCAS by NI medical ltd.) for cardiac output, Total peripheral resistance and other NICAS derived parameters.

Patients fluid balance will be planned according to these parameters and the rate of liberation from ventilator and rate of worsening renal function will be measured

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EIT Assessment of Lung Volume and Tidal Distribution: A Comparison of Non-Invasive Ventilation Devices

NCT02930174

Spontaneous Ventilation

COMPLETED NA

Change In Diaphragmatic Thickness Predicts Extubation Success

NCT02656199

Mechanical Ventilation Complication

TERMINATED

Using Ultrasound to Study Respiratory Muscle Function in Critically Ill Patients

NCT03139695

Injury of Diaphragm Mechanical Ventilation Complication Critical Illness

COMPLETED

Using Electrical Impedance Tomography to Investigate the Relationship Between Airflow Rate During High-flow Oxygen Therapy and Pressure in Patients With Heart Failure Compared to Non-invasive Ventilation

NCT06107907

to Assess the Corresponding PEEP Values in NIV With CPAP Under Different Airflow Rates During HFOT in Heart Failure Patients

RECRUITING NA

Assessment of Occult Lung Stress During Lung Protective Mechanical Ventilation

NCT05675696

Acute Respiratory Distress Syndrome

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be divided into two groups , the study group and the control group randomly assigned by a computer program .

After obtaining written informed consent , cardiac monitoring will be carried out by means of a NiCAS patients in both groups.The physician will not be exposed to the measurement data of the patients in the control group. For the research group : Monitoring will be carried out once a day , preferably at the same time the first three days . An increase in time interval is possible in accordance with an improvement in the patient . Patients will be treated according to the protocol described in Figure 1. Also , a graphic description of the various treatment zones and the exclusion zone is presented in Figure 2 .

For the control group patients will be treated according to the usual ward protocols.

The basic rules are:

Avoiding over- drying by using parameter TBW .

* Avoidance of renal dysfunction by maintaining the cardiac output above 2.3 , and avoiding the use of beta-blocker overdose in cases of low cardiac output and bradycardia as a result of maintaining an average blood pressure over 70 .
* In cases of high peripheral resistance - Reduction of resistance while maintaining normal blood pressure .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Respiratory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NiCAS treated

Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.

If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics

Group Type EXPERIMENTAL

NiCAS treated

Intervention Type DEVICE

Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.

If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics

Non NiCAS treated

Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment

Group Type SHAM_COMPARATOR

Non NiCAS treated

Intervention Type DEVICE

Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NiCAS treated

Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.

If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics

Intervention Type DEVICE